Navigation Links
Mylan's Dey Pharma Partners with Meda to Market EpiPen® Auto-Injector in Europe
Date:12/23/2010

BASKING RIDGE, N.J., Dec. 23, 2010 /PRNewswire-FirstCall/ -- Dey Pharma, L.P. today announced that it has signed a license agreement with Meda, a leading international specialty pharma company headquartered in Sweden, for the exclusive marketing and distribution rights of EpiPen® (epinephrine) Auto-Injector in Europe. EpiPen Auto-Injector is used for emergency treatment of severe allergic reactions (anaphylaxis). Anaphylaxis can occur quickly, often within a couple of minutes, and may be life-threatening.

Dey Pharma President Carolyn Myers, Ph.D. commented: "It's been long known and understood that one of our primary objectives is to expand the growth and breadth of our EpiPen franchise. After a careful and thorough analysis, we are extremely pleased to partner with Meda, a company with a strong and proven expertise in the allergy category as well as an expansive pan-European marketing platform. This collaboration strategically positions us to grow the EpiPen franchise and expand access to this important product in Europe. Many Europeans are at risk for an allergic emergency, some of whom don't even know it. Along with expanded educational programs, we plan to continue to grow the EpiPen Auto-Injector franchise in Europe, including the upcoming launch of our next generation EpiPen product with Meda."

EpiPen is a well-established brand and is the global market leader in the epinephrine auto-injector market. Beginning in 2011, the distribution rights to EpiPen Auto-Injector for Europe will be transferred to Meda from current distributors.

"EpiPen strengthens our allergy franchise in Europe, and we look forward to working closely with Dey to ensure that this important product is accessible to those who are at-risk of an allergic emergency, which may be life threatening," said Anders Lonner, CEO Meda AB.

Meda's exclusive rights to the product also include the next generation EpiPen Auto-Injector, featuring more patient-friendly features. The next generation EpiPen Auto-Injector is currently available in many markets outside of Europe, including the U.S. Meda will be responsible for regulatory filings in Europe.

Dey Pharma L.P., a subsidiary of Mylan Inc. (Nasdaq: MYL), is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases, severe allergic reactions and psychiatric disorders. The company puts patients first and facilitates efficient, cost-effective partnerships with customers. For more information, please visit www.dey.com.

Indications

EpiPen and EpiPen Jr. (0.3 and 0.15 mg epinephrine) Auto-Injectors are for the emergency treatment of severe allergic reactions (anaphylaxis) caused by allergens, exercise, or unknown triggers; and for patients who are at increased risk for these reactions.

EpiPen and EpiPen Jr. Auto-Injectors are designed for you to use immediately in an emergency, to treat an allergic reaction fast and give you time to get to a hospital or medical center. EpiPen and EpiPen Jr. Auto-Injectors are not a substitute for emergency medical treatment.

Important Safety Information

Each EpiPen Auto-Injector contains a single dose of a medicine called epinephrine, which you inject into your outer thigh. DO NOT INJECT INTRAVENOUSLY. DO NOT INJECT INTO YOUR BUTTOCK, as this may not be effective for a severe allergic reaction. In case of accidental injection, please seek immediate medical treatment.

Epinephrine should be used with caution if you have heart disease or are taking certain medicines that can cause heart-related (cardiac) symptoms.

Side effects may include an increase in heart rate, a stronger or irregular heartbeat, sweating, nausea and vomiting, difficulty breathing, paleness, dizziness, weakness or shakiness, headache, apprehension, nervousness, or anxiety. These side effects usually go away quickly, especially if you rest. If you have high blood pressure or an overactive thyroid, these side effects may be more severe or longer lasting. If you have heart disease, you could experience chest pain (angina). If you have diabetes, your blood sugar levels may increase after use. If you have Parkinson's disease, your symptoms may temporarily get worse.

For full prescribing information, please click here or visit www.epipen.com.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vista Partners Updates Coverage on Pro-Pharmaceuticals, Inc.; Maintains Target Price of $2.10
2. SCOLR Pharma, Inc. Announces Intention to Voluntarily Delist From NYSE AMEX Exchange
3. New Study Finds Pharmacists and Nurses are the Most Effective Health Care Voices in Promoting Medication Adherence
4. ISTA Pharmaceuticals Announces 2011 Guidance and Pipeline Update Webcast/Conference Call on January 5, 2011
5. Jazz Pharmaceuticals Announces New Patent Issued for Sodium Oxybate
6. Arena Pharmaceuticals to Host Conference Call and Webcast to Provide Update Following Lorcaserin End-of-Review Meeting With FDA
7. URAC Releases Revised Standards in Three of Its Industry-Leading Pharmacy Quality Management® Accreditation Programs
8. Generational Equity Announces Sale of B-Pharm, Inc. dba Remedies Pharmacy to a Private Investment Group
9. MAP Pharmaceuticals Announces Completion of LEVADEX™ Open-Label Safety Trial
10. Bellicum Pharmaceuticals Announces $3 Million in Convertible Note Funding
11. Lotus Pharmaceuticals Announces Change of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... 21, 2017 Cadence Design Systems, Inc. (NASDAQ: ... Tensilica ® Fusion F1 DSP is part of the ... The licensable IP targets SoCs designed for battery-powered sensor nodes ... leveraged the Fusion F1 DSP both to implement the IEEE ... trigger, audio identification and sensor fusion on a single DSP. ...
(Date:2/21/2017)... and Markets has announced the addition of the "Rosacea Drugs Price ... ... Analysis and Strategies - 2016, provides drug pricing data and benchmarks in ... What are the key drugs marketed for Rosacea ... market? What are the unit prices and annual treatment ...
(Date:2/20/2017)... , Feb. 21, 2017 Taiwan Biophotonic ... provider of non-invasive vital signs sensing solutions, today announced ... first finger-free wrist pulse oximeter, the oCare TM Pro ... wearable healthcare and medical devices space.  tBPC,s ... provides a non-invasive, simple and reliable method to measure ...
Breaking Medicine Technology:
(Date:2/21/2017)... ... 21, 2017 , ... Hanna Boys Center http://www.hannacenter.org ... the keynote speaker at its second Professional Networking Breakfast on March 9, 2017. ... comprehensive strategies to create and expand opportunities for boys and young men of ...
(Date:2/21/2017)... ... February 21, 2017 , ... As recently as 2015, rhinoplasty was one of ... of Plastic Surgeons. Some patients want to make a change in the appearance of ... their breathing ability. The team at usrhinoplasty.org is expanding its article database ...
(Date:2/21/2017)... (PRWEB) , ... February 21, 2017 , ... Ray Insurance ... communities in and around Tarrant County, is embarking on a six month charity event ... and treatments for cancer. , Cancer is one of the deadliest diseases in America; ...
(Date:2/21/2017)... ... February 21, 2017 , ... American Veterinarian™, the premier multimedia ... launching its first bi-monthly issue of 2017 in February. The inaugural issue will ... One Health. , In making the announcement, American Veterinarian™ Publisher Chris Hennessy ...
(Date:2/21/2017)... ... 2017 , ... Each February the nation reflects upon African ... American History Month ). This month-long celebration encourages reflection upon the ... people, but also the opportunity to examine the trends of addiction among African ...
Breaking Medicine News(10 mins):